Development and commercialization of novel diagnostic assays for the early detection of acute dengue virus infection. Dengue is an emerging disease of the tropics and is endemic in more than 100 countries with up to 100 million cases annually. Of these, 500,000 result in dengue haemorrhagic fever (DHF), a serious life-threatening complication of dengue virus infection. Dengue activity in northern Australia has increased in recent years with suggestions that it may be coming endemic in this count ....Development and commercialization of novel diagnostic assays for the early detection of acute dengue virus infection. Dengue is an emerging disease of the tropics and is endemic in more than 100 countries with up to 100 million cases annually. Of these, 500,000 result in dengue haemorrhagic fever (DHF), a serious life-threatening complication of dengue virus infection. Dengue activity in northern Australia has increased in recent years with suggestions that it may be coming endemic in this country. Early diagnosis, using NS1 based assays should facilitate containment of such outbreaks through earlier identification, treatment, isolation and strategic mosquito control.Read moreRead less
Antiviral compounds to inhibit the replicase of hepatitis C virus. Hepatitis C virus is a major public health problem. There are currently 200,000 infected individuals in Australia and 16,000 new infections every year. There is no specific treatment and current therapy treats a small percentage of patients only, which consists of interferon-alpha and ribavirin. This results in side effects and only a 50% cure rate. This study's outcomes are expected to lead to greater access to treatment and imp ....Antiviral compounds to inhibit the replicase of hepatitis C virus. Hepatitis C virus is a major public health problem. There are currently 200,000 infected individuals in Australia and 16,000 new infections every year. There is no specific treatment and current therapy treats a small percentage of patients only, which consists of interferon-alpha and ribavirin. This results in side effects and only a 50% cure rate. This study's outcomes are expected to lead to greater access to treatment and improved therapy resulting in higher cure rates and in a dramatic reduction in the cost of treating patients. A novel therapy will provide considerable benefits for the national biotechnology industry.Read moreRead less